| Literature DB >> 35936621 |
Ayush M Makkar1, Snigdha Komakula1, Ayush Agarwal1, Saumya Sahu2, Vaishali Suri2, Achal K Srivasatava1.
Abstract
Entities:
Year: 2022 PMID: 35936621 PMCID: PMC9350790 DOI: 10.4103/aian.aian_815_21
Source DB: PubMed Journal: Ann Indian Acad Neurol ISSN: 0972-2327 Impact factor: 1.714
Diagnostic Criteria for Rasmussen’s encephalitis
| PART A (ALL THREE) |
| 1. Clinical: Focal seizures (with or without epilepsia partialis continua) and unilateral cortical deficits |
| 2. EEG: Unihemispheric slowing with or without epileptiform discharges |
| 3. MRI: Unihemispheric focal cortical atrophy and at least one of the following: |
| Grey or white matter T2/FLAIR hyperintense signal |
| Hyperintense signal or atrophy of the ipsilateral caudate head |
| OR Part B (two of three) |
| 1. Clinical: Epilepsia partialis continua or progressive* unilateral cortical deficits |
| 2. MRI: Progressive* unihemispheric focal cortical atrophy |
| 3. Histopathology: T cell-dominated encephalitis with activated microglial cells typically, but not necessarily, forming nodules and reactive astrogliosis; numerous parenchymal macrophages, B cells, or plasma cells or viral inclusion bodies exclude the diagnosis of Rasmussen’s encephalitis |
Figure 1(a) MRI Brain demonstrating left hemispheric atrophy (predominantly perisylvian, caudate and putamen). (b) EEG showing 3.5–4 Hz spike and wave discharges and polyspikes localised to the left frontal lobe
Figure 2Histopathological specimen. (a) H and E stain from hippocampus, shows loss of neurons and ischemic changes in neurons at pyramidal layer. (b) Neu-N immunostain highlights the dispersion of neurons at pyramidal layer. (c) Neu-N immunostain highlights the cortical dyslamination of neurons and loss of neurons with ischemic changes. (d) GFAP immunostain highlights the supial gliosis